Document:

Document

Exhibit 10.1

CONSULTANT AGREEMENT

This Consultant Agreement ("Agreement") is between Appian Corporation, located at 7950 Jones Branch Drive, McLean, Virginia 22102 (“Appian”), and Bill McCarthy (“Consultant”).  This Agreement shall be effective as of the last date this Agreement is signed in the signature block below (“Effective Date”).   Appian and Consultant may be individually referred to as a Party or collectively referred to as the Parties. 

1.     Services and Effect on Prior Contract

Consultant shall serve as Acting Chief Operating Officer, working with Appian’s Go to Market Sales and Marketing teams to improve processes and programs and assist in development of sales pipeline.

Appian will compensate Consultant at the annual rate of $2,000 per hour.

By entering into this agreement, the parties agree that the Consultant Agreement between the parties dated May 11, 2021 is terminated and Consultant shall not longer submit invoices under that agreement.

2.     Independent Contractor

Consultant shall be an independent contractor and not an employee or agent of Appian.  Consultant shall not at any time be eligible to participate in benefits of any sort which Appian offers to its employees.  Except as otherwise provided herein, Consultant is responsible for paying all ordinary and necessary expenses, including, but not limited to, all applicable taxes, workers’ compensation insurance, and state disability insurance. As an independent contractor, Consultant: 

(a)has the right to control and direct the means and methods of performing the Services, subject to Appian’s general direction;

(b)shall use his/her own tools, equipment, and supplies in performing the Services;
(c)maintains a place of business at a location other than at Appian’s premises; and 
(d)is free to accept other work for other clients, provided such work does not interfere with Consultant’s obligations to perform the Services pursuant to the Statement of Work.

3.     Invoicing and Payment

3.1     Invoice Schedule. Consultant shall invoice Appian on a monthly basis in arrears, based on Consultant’s good faith estimate of the number of hours spent providing services under this agreement.  

3.2      Payment. Invoices shall be payable within thirty (30) days of Appian’s receipt of a correct and properly documented invoice, provided that Appian may withhold from any payment any amount incorrectly invoiced or in dispute.  Invoices must be submitted to the following address (or such other address to which Appian notifies Consultant): 

Accounts Payable
Appian Corporation 
7950 Jones Branch Drive
McLean, Virginia 22182

3.3    Expenses. Appian will only reimburse Consultant for those expenses and which are approved advance and in writing by Matthew Calkins.  Invoices for reimbursable expenses must include copies of all the corresponding receipts.

3.4    Taxes.  Consultant shall comply with all federal and state benefits laws applicable to Consultant, including making deductions and contributions for social security and unemployment taxes.  Each Party shall be responsible for the payment of other taxes, if any, imposed upon it in connection with, or as a result of, this Agreement.

4.     Audit and Records

Exhibit 10.1

Consultant shall maintain books and records supporting all fees and reimbursable expenses invoiced to Appian under this Agreement.  During the term of this Agreement and for one (1) year thereafter, Appian shall have access to such books and to all other records of Consultant as required to verify Consultant’s invoices.

5.     Warranty 

Consultant represents and warrants as follows: 

5.1    All materials and/or work product created, in the process of being created, or delivered to Appian (or Appian’s customer) in accordance with this Agreement or which may otherwise result from the Services and which was not provided by Appian (collectively, the “Materials”) is original material or material which has been properly licensed from third parties and has been used by Consultant consistent with such licenses. 

5.2    The Materials or any part thereof have not been assigned, transferred, or otherwise encumbered, do not infringe any patents, copyrights, trade secrets or other proprietary rights of any third party, and Consultant has no reason to believe that any such infringement or claims thereof could be made by third parties. 

5.3    The Services will be performed in a professional and workmanlike manner consistent with prevailing industry standards.  

5.4    Consultant has all necessary licenses, work permits or other government approvals required of Consultant to perform the Services, to specifically include compliance with applicable immigration and non-immigration codes, rules and regulations.   Consultant warrants that he has the approval of his employer to provide the services.

5.5    Consultant will neither undertake, nor cause or permit to be undertaken, any activity which either (a) is illegal under any laws, decrees, rules, or regulations in effect in the United States, or (b) would have the effect of causing Appian to be in violation of any laws, decrees, rules or regulations in effect in the United States or elsewhere.  In particular, and without limiting the generality of the foregoing, Consultant agrees not to, directly or indirectly, give, offer, promise, authorize, or tolerate to be given, offered or promised, anything of value to an official or employee of any customer or potential customer of Appian with the intent to (i) influence any official act or decision of such official or employee, or (ii) induce such official or employee to use its influence to affect or influence any act or decision of the potential or actual customer.

5.6    Consultant has performed reasonable background checks on all Consultant personnel who perform the Services, and such personnel have passed such background checks.  Upon Appian’s written request, Consultant will confirm that any Consultant personnel identified by Appian have passed these background checks.

6.     Confidentiality 

6.1    Confidential Information. The term "Confidential Information" means any information, materials or data, in any medium, disclosed by Appian to the Consultant which (a) is disclosed in writing and marked confidential, (b) is disclosed orally and identified as Confidential Information at the time of disclosure, or (c) should reasonably have been understood by Consultant to be confidential because of the circumstances of disclosure or the nature of the information disclosed.  Confidential Information shall not include information that (i) has become publicly known through no wrongful act of Consultant, (ii) has been rightfully received from a third party authorized to make such communication without restriction, (iii) has been independently developed by Consultant without reliance upon the Confidential Information, (iv) has been approved for release by written authorization by Appian, or (v) is required to be disclosed as a matter of law; provided that Consultant promptly notifies Appian of the request for disclosure and provides Appian reasonable assistance and cooperation to enable Appian to obtain a protective order.  

6.2    Confidentiality Obligations. Confidential Information shall remain Appian’s property.  Consultant may only use the Confidential Information as reasonably necessary to perform the Services.  Consultant may not disclose the Confidential Information to any third party without Appian’s express prior written consent.  Consultant will protect the Confidential Information from unauthorized use and disclosure using the same means it uses to protect its own information and data of like importance, but in no event using less than a reasonable degree of care.  Consultant will immediately notify Appian of any actual or threatened unauthorized use or disclosure of the Confidential Information.  Consultant agrees to reasonably assist Appian in remedying any such unauthorized use or disclosure, and Consultant shall be responsible for any breach of this 

Exhibit 10.1

Agreement by those receiving Confidential Information by or through Consultant.  Consultant’s ability to use the Confidential Information shall automatically expire upon the earlier of Consultant no longer requiring the Confidential Information to perform the applicable Services or upon the termination or expiration of the Agreement.  Within ten (10) business days after the expiration or termination of the Agreement, Consultant shall return all copies of the Confidential Information to Appian or certify to Appian that all Confidential Information has been destroyed.

7.  Ownership of Intellectual Property 

7.1    General. Except as noted in Section 7.2 below, the Materials shall be a “Work Made For Hire” and Appian shall own all right, title and interest in and to the Materials, including, without limitation, all intellectual property rights therein.  To the extent the Materials are determined not to constitute a “Work Made For Hire” as a matter of law, Consultant irrevocably assigns and transfers all right, title and interest in such Materials to Appian upon the Material being made.  To the maximum extent permitted by applicable law, Consultant waives all moral rights in the Materials.  At the request and expense of Appian, Consultant shall take such steps as may be necessary or desirable, in Appian’s reasonable discretion, in order for Appian to secure, or for Consultant to assign, transfer and convey any of the foregoing to Appian (or its nominee).

7.2    Pre-existing Material. Consultant shall retain ownership in any preexisting proprietary materials that are contained in the Materials, provided Consultant specifically identifies such materials to Appian in advance.  Appian shall own all pre-existing material (including all intellectual property rights therein) that is not identified by Consultant.  To the extent such pre-existing materials are incorporated into the Materials and identified by Consultant, Consultant grants to Appian an irrevocable, nonexclusive, worldwide, royalty free, transferable license to use, execute, reproduce, display, perform, distribute copies of, and prepare derivative works based upon, such preexisting materials, and to authorize, or sub-license others to do any, some or all of the foregoing. 

8.     Term and Termination

8.1    Term. This Agreement shall be effective upon the Effective Date and, unless terminated earlier as set forth below, shall remain in effect for a term of one year, unless extended further by the parties in writing.

8.2    Termination. This Agreement shall terminate upon the occurrence of any of the following: 

(a)Appian may terminate this Agreement for its convenience upon providing Consultant with no less than ten (10) calendar days prior written notice.  
(b)    Either Party may terminate this Agreement if the other Party commits a material breach of the terms of this Agreement and fails to cure such breach within thirty (30) calendar days after receiving written notice of the breach from the other, non breaching Party. 

8.3    Rights Upon Termination. Upon the effective date of termination, Consultant shall stop performing the Services specified in such termination notice and Appian shall compensate Consultant as follows: Appian shall pay for all work accepted by Appian prior to the effective date of termination.  All Materials in Consultant’s possession at the time of such cancellation or termination shall be immediately forwarded to Appian.  All licenses granted under or pursuant to this Agreement by Consultant to Appian are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, or replacement provision therefore (the "Code"), licenses to rights to "intellectual property" as defined in the Code. The Parties agree that Appian, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code. The Parties further agree that, in the event of the commencement of bankruptcy proceedings by or against Consultant under the Code, Appian shall be entitled to retain all of its rights under the Agreement. 

9.     Restrictive Covenants 

Consultant acknowledges that Appian invests significant resources in the training and development of its employees and invests significant resources in the marketing to and development of its business opportunities.  In light of these understandings, Consultant agrees that the following restrictions on Consultant’s conduct are reasonably designed to protect Appian’s legitimate business interests without unreasonably restricting Consultant’s ability to seek or obtain work.

During the term of this Agreement, and for a period of twelve (12) months from the date this Agreement expires or is terminated, Consultant agrees (a) not to induce or solicit any Appian employee to terminate his or her employment or to seek or 

Exhibit 10.1

accept any employment with any other business entity that performs competing services; and (b) not to perform any services for a client for whom services were performed on behalf of Appian under this Agreement, provided that Consultant may be engaged by or provide services to a division of such a client that is not involved in any way as a user or beneficiary of deliverables from the Services.

10.    Governing Law and Dispute Resolution.

10.1 Governing Law. The validity, construction, and interpretation of this Agreement shall be governed by the laws of the Commonwealth of Virginia, excluding its principles of conflict of laws, and the controlling laws of the United States of America, as applicable.  This Agreement will not be governed by the United Nations Convention of Contracts for the International Sale of Goods, the application of which is hereby expressly excluded.

10.2 Arbitration. Any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by arbitration in the County of Fairfax, Virginia in accordance with the Rules of the American Arbitration Association (“AAA”) by a single arbitrator to be designated by AAA, and judgment upon the decision rendered by the arbitrator may be entered in any court having jurisdiction thereof.  Any decision by the arbitrator shall be final and binding, and except in cases of fraud or gross misconduct by the arbitrator, the decision rendered shall not be appealable.  The prevailing Party in the arbitration proceeding shall be entitled to recover attorney’s fees, all reasonable out-of-pocket costs and disbursements, as well as any and all charges which may be made for the arbitration’s cost and the fees of the arbitrator.  Notwithstanding the foregoing, either Party may seek preliminary equitable or injunctive relief from a court of competent jurisdiction to avoid irreparable harm resulting from or which may result from the other Party’s breach or threatened breach of this Agreement.  

11.    Notices 

Any notices or other communications required or permitted to be given or delivered under this shall be in writing and shall be sufficiently given if sent by first class certified mail, or overnight delivery service using a reputable courier service, postage prepaid to the following address or such other address as may be specified in a written notice delivered in accordance with this Section.

If to Appian:                        If to Consultant:   

Appian Corporation                    Bill McCarthy
7950 Jones Branch Drive                              7413 Hasentree Club Drive
McLean, VA 22182                    Wake Forest, NC 27587  
Attention: Legal Department                

12.    General

12.1 Waiver. The waiver by either Party of a breach or right under this Agreement will not constitute a waiver of any other or subsequent breach or right. 

12.2 Severability. If any provision of this Agreement is found unenforceable, it and any related provisions will be interpreted to best accomplish the unenforceable provision’s essential purpose. 

12.3 Non-Assignability. Consultant may not assign its rights or delegate its duties under this Agreement, by operation of law or otherwise, without Appian’s express prior written consent.  Consultant may not subcontract any part of the Services to any third party without Appian’s express prior written consent. 

12.4 Entire Agreement. This Agreement and any Confidentiality Agreement, if applicable, are the entire agreement between Consultant and Appian regarding the subject matter hereof and supersede any prior or contemporaneous agreement, written or oral.  This Agreement and any Confidentiality Agreement, if applicable, may be modified only by written agreement signed by the duly authorized representatives of Consultant and Appian.  All section headings in this Agreement, and any Confidentiality Agreement, if applicable, are for convenience only and do not modify or restrict any of this Agreement’s  or Confidentiality Agreement’s terms.  

Exhibit 10.1

12.5     Public Announcements. Consultant agrees not to issue news releases, public announcements, or a statement or communication in an annual report or any other public forum concerning this Agreement without Appian’s express prior written consent, except as may be required in reports filed pursuant to federal securities regulations.

12.6    Signature. Original signatures transmitted and received via facsimile or other electronic transmission of a scanned document, (e.g., .pdf or similar format) are true and valid signatures for all purposes hereunder and shall bind the Parties to the same extent as original signatures.  

12.7     Survival. All provisions that by their terms or nature survive termination of this Agreement shall survive such termination. 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date last written below.

						
	CONSULTANT

	APPIAN CORPORATION

	Signed:    /s/ Bill McCarthy
	Signed:    /s/ Matthew Calkins

	Name:    Bill McCarthy
	Name:    Matthew Calkins

	Title:    
	Title:    CEO

	Date:   May 23, 2022
	Date:      May 27, 2022EXHIBIT 10.1
​
​

[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.
​
FIRST AMENDMENT TO LOAN AGREEMENT
This FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of April 7, 2022 (the “Effective Date”), is made by and among COHERUS BIOSCIENCES, INC., a Delaware corporation (as “Borrower” and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”).
Recitals
A.Collateral Agent, Lenders, Borrower and the other Credit Parties thereunder have entered into that certain Loan Agreement, dated as of January 4, 2022 (the “Loan Agreement”).
B.Collateral Agent and Lenders have determined that the Loan Agreement contains patent errors.
C.In accordance with Section 11.5 of the Loan Agreement, Borrower (acting for its own behalf and on behalf of the other Credit Parties), Collateral Agent and Lenders desire to amend the Loan Agreement to correct such errors on the terms and conditions set forth herein.
Agreement
Now, Therefore, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:
1.Definitions.  All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.  The rules of interpretation set forth in the first paragraph of Section 13.1 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.
2.Amendments to Loan Agreement.
a.The Loan Agreement shall be amended by deleting in its entirety the definition of Indebtedness in Section 13.1 of the Loan Agreement and replacing it as follows:

““Indebtedness” means, with respect to any Person, without duplication: (a) all indebtedness for advanced or borrowed money of, or credit extended to, such Person; (b) all obligations issued, undertaken or assumed by such Person as the deferred purchase price of assets, properties, services or rights (other than (i) accrued expenses and trade payables entered into in the ordinary course of business which are not more than one hundred and eighty (180) days past due or subject to a bona fide dispute, (ii) obligations to pay for services provided by 

​

EXHIBIT 10.1
​
​

employees and individual independent contractors in the ordinary course of business which are not more than one hundred and twenty (120) days past due or subject to a bona fide dispute, (iii) liabilities associated with customer prepayments and deposits, and (iv) prepaid or deferred revenue arising in the ordinary course of business), including (A) any obligation or liability to pay deferred purchase price or other similar deferred consideration for such assets, properties, services or rights where such deferred purchase price or consideration becomes due and payable solely upon the passage of time, and (B) any obligation described in clause (b) of the definition of “Contingent Obligation” that is due and payable (or that becomes due and payable) solely with the passage of time (and not upon the occurrence of an event or the performance of an act); (c) the face amount of all letters of credit issued for the account of such Person and, without duplication, all drafts drawn thereunder and all reimbursement or payment obligations with respect to letters of credit, surety bonds, performance bonds and other similar instruments issued by such Person; (d) all obligations of such Person evidenced by notes, bonds, debentures or other debt securities or similar instruments (including debt securities convertible into Equity Interests), including obligations so evidenced incurred in connection with the acquisition of properties, assets or businesses; (e) all indebtedness of such Person created or arising under any conditional sale or other title retention agreement or incurred as financing, in either case with respect to property acquired by such Person (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property); (f) all Capital Lease Obligations of such Person; (g) the principal balance outstanding under any synthetic lease, off-balance sheet loan or similar off balance sheet financing product by such Person; (h) Disqualified Equity Interests; (i) all indebtedness referred to in clauses (a) through (g) above of other Persons secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in assets or properties (including accounts and contracts rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such indebtedness of such other Persons; and (i) all Contingent Obligations of such Person described in clause (a) of the definition thereof.”
​
b.The Loan Agreement shall be amended by deleting in its entirety the definition of LIBOR Rate in Section 13.1 of the Loan Agreement and replacing it as follows:

““LIBOR Rate” means, as of any Interest Rate Determination Date (and for the Interest Period that follows such Interest Rate Determination Date), the rate per annum equal to the greater of (a) USD LIBOR as published on the applicable Bloomberg LIBOR page administered by the ICE Benchmark Administration for Dollars for a period equal in length to three (3) months to such Interest Period (or, in the event such rate does not appear on such page or screen, on any successor or substitute page on such screen that displays such rate, the rate per annum equal to the rate determined by the Collateral Agent to be the average of the rates per annum at which deposits in Dollars for delivery on the first day of such Interest Period in same day funds in the approximate amount of the Term Loans with a term equivalent to such Interest Period would be offered by three (3) major banks in the London interbank Eurodollar market at their request, determined as of approximately 11:00 a.m., London time, on such Interest Rate Determination Date), and (b) 1.00% per annum.  Unless otherwise specified in any amendment to this Agreement entered into in accordance with Section 2.3(e), in the event that a Benchmark Replacement with respect to the LIBOR Rate is implemented, then all references herein to LIBOR Rate shall be deemed references to such Benchmark Replacement.”
​
c.The Loan Agreement shall be amended by deleting in its entirety the definition of Term Loan and Term Loans in Section 13.1 of the Loan Agreement and replacing it as follows:

​

EXHIBIT 10.1
​
​

““Term Loan” means each of the Tranche A Loan, the Tranche B Loan, the Tranche C Note and the Tranche D Note, as applicable, and “Term Loans” means, collectively, the Tranche A Loan, the Tranche B Loan, the Tranche C Loan and the Tranche D Loan.’
​
d.The Loan Agreement shall be amended by deleting in its entirety the definition of Term Loan Commitment and Term Loan Commitments in Section 13.1 of the Loan Agreement and replacing it as follows:

““Term Loan Commitment” mean each of the Tranche A Loan Commitment, the Tranche B Loan Commitment, the Tranche C Loan Commitment and the Tranche D Loan Commitment, as applicable, and “Term Loan Commitments” means, collectively, the Tranche A Loan Commitment, the Tranche B Loan Commitment, the Tranche C Loan Commitment and the Tranche D Loan Commitment.”
​
e.The Loan Agreement shall be amended by deleting in its entirety the definition of Term Loan Note in Section 13.1 of the Loan Agreement and replacing it as follows:

““Term Loan Note” means the Tranche A Note, the Tranche B Note, the Tranche C Note or the Tranche D Note (as applicable), or any combination thereof, as the context dictates.”
​
f.The Loan Agreement shall be amended by deleting in its entirety the Collateral Agent’s notice details in Section 9 of the Loan Agreement and replacing it as follows:

“BioPharma Credit PLC
c/o Beaufort House
51 New North Road
Exeter EX4 4EP
United Kingdom
Attn:  Company Secretary
Tel:  [***]
Fax:  [***]
Email:  [***]
​
g.The Loan Agreement shall be amended by deleting in its entirety the facsimile number for BioPharma Limited Partnership in Exhibit D of the Loan Agreement and replacing it as follows:

“Fax:  [***]”
3.Representations and Warranties; Reaffirmation; Covenant to Deliver.  
a.Borrower hereby represents and warrants to each Lender and the Collateral Agent as follows:
	i.		Borrower has all requisite power and authority to enter into this Amendment and to carry out the transactions contemplated hereby.

	ii.		This Amendment has been duly executed and delivered by Borrower and is the legally valid and binding obligation of such Person, enforceable against such Person in accordance with its respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws 

​

EXHIBIT 10.1
​
​

			relating to or limiting creditors’ rights generally or by general principles of equity.

	iii.		The execution, delivery and performance by Borrower of this Amendment have been duly authorized and do not and will not: (A) contravene the terms of such Person’s Operating Documents; (B) violate any Requirements of Law, except to the extent that such violation could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (C) conflict with or result in any breach or contravention of, or require any payment to be made under any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or affecting such Person or the assets or properties of such Person or any of its Subsidiaries or any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which such Person or any of its properties or assets are subject, except to the extent that such conflict, breach, contravention or payment could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (D) require any Governmental Approval, or other action by, or notice to, or filing with, any Governmental Authority (except such Governmental Approvals or other actions, notices and filings which have been duly obtained, taken, given or made on or before the Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (E) require any approval, consent, exemption or authorization, or other action by, or notice to, or filing with, any Person other than a Governmental Authority, including such Person’s stockholders, members or partners,  (except such approvals, consents, exemptions, authorizations, actions, notices and filings which have been or will be duly obtained, taken, given or made on or before the Effective Date and are in full force and effect), except for those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; or (F) constitute a material breach of or a material default under (which such default has not been cured or waived) or an event of default (or the equivalent thereof, however described) under, or could reasonably be expected to give rise to the cancellation, termination or invalidation of or the acceleration of such Person’s or any Subsidiary’s obligations under, any Material Contract.

b.Borrower hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein.  By executing this Amendment, Borrower acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment.

4.References to and Effect on Loan Agreement.  Except as specifically set forth herein, this Amendment shall not modify or in any way affect any of the provisions of the Loan Agreement, which shall remain in full force and effect and is hereby ratified and confirmed in all respects.  On and after the Effective Date, all references in the Loan Agreement to “this Agreement,” “hereto,” “hereof,” “hereunder,” or words of like import shall mean the Loan Agreement as amended by this Amendment.
5.Successors and Assigns.  This Amendment binds and is for the benefit of Borrower, the 

​

EXHIBIT 10.1
​
​

other Credit Parties, Lenders and Collateral Agent and each of their respective successors and permitted assigns.
6.Governing Law; Venue; Jury Trial Waiver.    This Amendment shall be construed in accordance with and governed by the law of the State of New York.  The provisions of Section 10 (Choice of law, Venue and Jury Trial Waiver Etc.) of the Loan Agreement shall apply hereto as if more fully set forth herein as if references therein to “this Agreement” were references to this Amendment.
7.Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment.  Delivery of an executed counterpart of this Amendment electronically or by facsimile shall be effective as delivery of an original executed counterpart of this Amendment.

[Remainder of Page Intentionally Left Blank]
​

​

EXHIBIT 10.1
​
​

IN WITNESS WHEREOF, the undersigned hereto have caused this Amendment to be executed as of the date first written above by each of their officers thereunto duly authorized.
COHERUS BIOSCIENCES, INC.,
as Borrower and a Credit Party on its own behalf and on behalf of each other Credit Party
​
​
​
By____/s/ Dennis M. Lanfear______________________
Name: Dennis M. Lanfear
Title: Chief Executive Officer
​
​
​
​
​
​
​
​

​

​

BIOPHARMA CREDIT PLC,
as Collateral Agent
By:  Pharmakon Advisors, LP,
its Investment Manager
By:  Pharmakon Management I, LLC,
its General Partner
By_____/s/ Pedro Gonzalez de Cosio_______________
Name:  Pedro Gonzalez de Cosio
Title:  Managing Member
BPCR LIMITED PARTNERSHIP,
as a Lender
​
​
By: Pharmakon Advisors, LP, 
its Investment Manager
​
By: Pharmakon Management I, LLC,
its General Partner
​
By_____ /s/ Pedro Gonzalez de Cosio_______________
Name:  Pedro Gonzalez de Cosio
Title:  Managing Member
​
BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP,
as Lender
By:BioPharma Credit Investments V GP LLC,
its general partner
​
By:  Pharmakon Advisors, LP,
its Investment Manager
By____/s/ Pedro Gonzalez de Cosio________________
Name:  Pedro Gonzalez de Cosio
Title:  CEO and Managing Member

​
US-DOCS\131166251.5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]